Literature DB >> 14730265

National disease burden of respiratory viruses detected in children by polymerase chain reaction.

Kelly J Henrickson1, Susan Hoover, K Sue Kehl, Weimin Hua.   

Abstract

BACKGROUND: The epidemiology of community-acquired respiratory viruses at the Children's Hospital of Wisconsin between 1996 and 1998 was examined with molecular [multiplex (M) PCR] and standard virologic methods. METHODS AND
RESULTS: A total of 3325 patients with lower respiratory infection (LRI) [bronchiolitis (42%), pneumonia (38%) and croup (12%)] were identified. It is estimated that 545,000 LRI hospitalizations occur each year in the United States in children younger than 18 years old (viral, 428,000; pneumonia, 221,000; bronchiolitis, 222,000; croup, 65,000), including a continued increase in bronchiolitis hospitalizations (47.8/1000; <1 year). The most common viruses detected each year in hospitalized children included respiratory syncytial virus (A and B; 117,000), parainfluenza virus (PIV-1 and -2, 48 000; PIV-3, 18,000) and influenza (A and B, 39,000). With multiplex reverse transcription polymerase chain reaction (MPCR), different patient populations demonstrated different LRI epidemiology in relation to specific syndromes and viral causes. At least 21% of LRI hospitalizations were in children with significant medical problems.PIVs were detected much more frequently in immunocompromised children than in previously healthy children (33% vs. 16%). Similarly 15% of respiratory syncytial virus was detected between May and October, mostly in immunocompromised children. Influenza caused 19% of bronchiolitis in previously healthy children, and no virus could be reliably predicted based on clinical presentation, including wheezing. Of children hospitalized for LRI, 40% tested positive for the seven most common respiratory viruses by MPCR.
CONCLUSIONS: Work is under way to expand the number of viruses detected by MPCR and to determine whether newly discovered viruses, such as human metapneumovirus, contribute to the burden of pediatric LRI hospitalizations.

Entities:  

Mesh:

Year:  2004        PMID: 14730265     DOI: 10.1097/01.inf.0000108188.37237.48

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  97 in total

1.  Interleukin-27 inhibits vaccine-enhanced pulmonary disease following respiratory syncytial virus infection by regulating cellular memory responses.

Authors:  Ruihong Zeng; Huixian Zhang; Yan Hai; Yuxiu Cui; Lin Wei; Na Li; Jianxun Liu; Caixia Li; Ying Liu
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

Review 2.  Real-time PCR in clinical microbiology: applications for routine laboratory testing.

Authors:  M J Espy; J R Uhl; L M Sloan; S P Buckwalter; M F Jones; E A Vetter; J D C Yao; N L Wengenack; J E Rosenblatt; F R Cockerill; T F Smith
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

3.  Live-cell characterization and analysis of a clinical isolate of bovine respiratory syncytial virus, using molecular beacons.

Authors:  Philip Santangelo; Nitin Nitin; Leslie LaConte; Amelia Woolums; Gang Bao
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

4.  The comparative genomics of human respiratory syncytial virus subgroups A and B: genetic variability and molecular evolutionary dynamics.

Authors:  Lydia Tan; Frank E J Coenjaerts; Lieselot Houspie; Marco C Viveen; Grada M van Bleek; Emmanuel J H J Wiertz; Darren P Martin; Philippe Lemey
Journal:  J Virol       Date:  2013-05-22       Impact factor: 5.103

5.  Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus.

Authors:  Rebekka Kohlmann; Sarah Schwannecke; Bettina Tippler; Nicola Ternette; Vladimir V Temchura; Matthias Tenbusch; Klaus Uberla; Thomas Grunwald
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

6.  Analysis of nucleotides 13-96 of the human parainfluenza virus type 3 antigenomic promoter reveals positive- and negative-acting replication elements.

Authors:  Jill R Gander; LeeAnne M Schwan; Michael A Hoffman
Journal:  Virology       Date:  2011-08-30       Impact factor: 3.616

7.  Effect of hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 on growth and pathogenicity of Sendai/human parainfluenza type 3 chimera virus in mice.

Authors:  Makiko Watanabe; Vasiliy P Mishin; Scott A Brown; Charles J Russell; Kelli Boyd; Y Sudhakara Babu; Garry Taylor; Xiaoping Xiong; Xiaowei Yan; Allen Portner; Irina V Alymova
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

Review 8.  The airway epithelium: soldier in the fight against respiratory viruses.

Authors:  Marjolaine Vareille; Elisabeth Kieninger; Michael R Edwards; Nicolas Regamey
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

9.  Alveolar macrophages are a major determinant of early responses to viral lung infection but do not influence subsequent disease development.

Authors:  Philippa K Pribul; James Harker; Belinda Wang; Hongwei Wang; John S Tregoning; Jürgen Schwarze; Peter J M Openshaw
Journal:  J Virol       Date:  2008-02-20       Impact factor: 5.103

10.  Multipathogen infections in hospitalized children with acute respiratory infections.

Authors:  Dan Peng; Dongchi Zhao; Jingtao Liu; Xia Wang; Kun Yang; Hong Xicheng; Yang Li; Fubing Wang
Journal:  Virol J       Date:  2009-09-29       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.